SAN DIEGO, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share, as well as the full exercise of the option granted to the underwriters to purchase an aggregate of 498,000 additional shares of common stock. The gross proceeds to Receptos from this offering were approximately $117.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Receptos.
Help employers find you! Check out all the jobs and post your resume.
